PDUFA dates January 2023: FDA calendar and catalysts.
0 PDUFA dates fell in January 2023. The FDA calendar also recorded 26 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in January 2023
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
January 2023: other FDA decisions and filings
January 2023: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jan 2023Month disclosed | RYTELO (imetelstat) | GERN | Topline readout | — | Positive | SEC Form 10-Q |
| Jan 2023Month disclosed | NERD-301 | PHAT | Topline readout | Non-Erosive reflux disease, or Non-Erosive GERD | Positive | SEC Form 10-K |
| Jan 2023Month disclosed | TRUTAKNA (atacicept) | VERA | Topline readout | — | Positive | sec_424b |
| Jan 2023Month disclosed | — | VERA | Topline readout | — | Positive | SEC Form 10-K |
| January 12, 2023 | — | ORMP | Topline readout | — | Missed primary endpoint | SEC Form 10-K |
| January 19, 2023 | OXY-101 | XRTX | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| January 27, 2023 | — | LEGN | Interim readout | — | Met primary endpoint | SEC Form 10-K |
January 2023: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jan 2023Month disclosed | MP0533 | MOLN | Trial start | r/r AML and AML/MDS | Completed | SEC Form 10-K |
| Jan 2023Month disclosed | aleniglipron (GSBR-1290) | GPCR | Trial start | — | Completed | SEC Form 10-Q |
| January 27, 2023 | ATR-12 | AZTR | Trial start | — | Completed | sec_s1 |
Questions
What PDUFA dates are in January 2023?
0 PDUFA dates fell in January 2023. The FDA calendar also recorded 26 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.